BeOne Medicines Ltd

ONC

Market cap $37.7B

Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest performing sectors and is the portfolio's biggest relative detractor in relative returns YTD. Geographically, international markets have led domestic markets notably YTD, largely reflecting depressed valuations after a multiyear lag.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton's tyrosine kinase (BTK) inhibitor. “Sonrotoclax is a.

Pharma stocks can be the most rewarding of all equities. BeOne Medicines is offering a chance to climb on board amid a powerful rally.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, advances its vision to become the world's leading oncology company with extensive new data from its differentiated hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 6-9. Nearly 50 abstracts have been accepted, including six oral presentations, featuring the company's three transformative appr.

BeOne Medicines AG ( ONC ) Jefferies London Healthcare Conference 2025 November 17, 2025 11:00 AM EST Company Participants John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon, everyone.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including.

BeOne stock is approaching a new buy point following the company's strong third-quarter report that saw cancer drug sales surge.

BeOne Medicines AG ( ONC ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 9:30 AM EST Company Participants Aaron Rosenberg - Chief Financial Officer John Scotti Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division Let's chat with BeOne Medicines. My name is Michael Schmidt, senior biotech analyst with Guggenheim.

BeOne Medicines AG ( ONC ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Maller John Oyler - Co-Founder, Executive Chairman & CEO Aaron Rosenberg - Chief Financial Officer Wang Lai - Global Head of Research & Development Xiaobin Wu - President, COO & GM of China Mark Lanasa - Senior VP & Chief Medical Officer for Solid Tumors Matt Shaulis Conference Call Participants Yaron Werber - TD Cowen, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Andrew Berens - Leerink Partners LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Leonid Timashev - RBC Capital Markets, Research Division Sean Laaman - Morgan Stanley, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yuxi Dong - Jefferies LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, everyone. Welcome to BeOne Medicine's Q3 2025 Earnings Call Webcast.

While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.